{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:20:10Z","timestamp":1785799210367,"version":"3.56.0"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of advanced gastric cancer (GC). However, acquired resistance remains common. For patients who initially benefit and later progress, immunotherapy rechallenge is biologically plausible but still investigational.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach<\/jats:title>\n                    <jats:p>This narrative review synthesizes mechanistic, translational, biomarker, and clinical evidence on ICI resistance and rechallenge in GC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Resistance may involve tumor-intrinsic plasticity, hypoxia- and metabolism-driven remodeling, impaired antigen presentation, suppressive tumor microenvironment (TME) components, T-cell exhaustion, and compensatory checkpoints such as Lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), T-cell immunoreceptor with Ig and ITIM domains(TIGIT), and V-domain Ig suppressor of T cell activation (VISTA). Epstein-Barr virus (EBV)-positive and Microsatellite instability-high (MSI-H)\/Deficient mismatch repair (dMMR) tumors often show immune-inflamed features, but they may still develop HLA class I loss, immune editing, or cold-tumor phenotypes. Direct GC-specific rechallenge evidence remains limited and is mainly retrospective or case-series based. Therefore, mechanistic and non-GC data should be interpreted as indirect and hypothesis-generating.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICI rechallenge in GC should be regarded as a biomarker-informed investigational strategy rather than a standard of care. Prospective trials, standardized definitions, validated biomarkers, and careful toxicity monitoring are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1820652","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:46:23Z","timestamp":1779255983000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy rechallenge in gastric cancer: resistance mechanisms, molecular stratification, and precision decision-making"],"prefix":"10.3389","volume":"17","author":[{"given":"Yu-cai","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Affiliated Hospital of Putian University","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-lin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Putian University","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-gui","family":"Fu","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Technology, Putian University","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-jin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Hospital of Putian University","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.934249","article-title":"Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review","volume":"12","author":"Shen","year":"2022","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","article-title":"Overcoming immunotherapy resistance in gastric cancer: Insights into mechanisms and emerging strategies","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e000404","DOI":"10.1136\/jitc-2019-000404","article-title":"Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal Malignancies","volume":"8","author":"Puccini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38710","article-title":"Programmed death receptor-1\/programmed death-ligand 1 inhibitors: Clinical progress and biomarker exploration in gastric cancer","volume":"10","author":"Shi","year":"2024","journal-title":"Heliyon"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104837","article-title":"Recent advances in tumour microenvironment impact immunotherapy resistance in gastric cancer","volume":"215","author":"Sun","year":"2025","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","article-title":"An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells","volume":"53","author":"Kumagai","year":"2020","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001253","article-title":"Intratumoral immune response to gastric cancer varies by molecular and histologic subtype","volume":"43","author":"Kim","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10513","article-title":"Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status","volume":"18","author":"Valentini","year":"2019","journal-title":"Oncol Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.803974","article-title":"Cancer stem cells and the tumor microenvironment in gastric cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41419-024-06875-4","article-title":"IL-4\/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcgamma receptor IIB in M2 macrophages","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2596","article-title":"CD4\/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v14.i1.216","article-title":"Immune evasion mechanisms and therapeutic strategies in gastric cancer","volume":"14","author":"Ma","year":"2022","journal-title":"World J Gastrointestinal Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0089","article-title":"The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer","volume":"17","author":"Fan","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00533","article-title":"Regulatory T cells and plasmacytoid dendritic cells within the tumor microenvironment in gastric cancer are correlated with gastric microbiota dysbiosis: A preliminary study","volume":"10","author":"Ling","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/03008916211070051","article-title":"The tumor immune-microenvironment in gastric cancer","volume":"108","author":"Fang","year":"2022","journal-title":"Tumori"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-732","article-title":"Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: A retrospective multi-center cohort study","volume":"11","author":"Lin","year":"2022","journal-title":"Trans Lung Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10565-024-09917-x","article-title":"Mechanisms of HIF1A-mediated immune evasion in gastric cancer and the impact on therapy resistance","volume":"40","author":"Qi","year":"2024","journal-title":"Cell Biol Toxicol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2146","article-title":"A bibliometric analysis of metabolic reprogramming in the tumor microenvironment from 2003 to 2022","volume":"7","author":"Xi","year":"2024","journal-title":"Cancer Rep (Hoboken NJ)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/qub2.70027","article-title":"Metabolic-immune interactions in gastric cancer T cells: A single-cell atlas for prognostic biomarker identification","volume":"14","author":"Liu","year":"2026","journal-title":"Quantitative Biol (Beijing China)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39639","DOI":"10.1038\/s41598-025-23300-8","article-title":"Cancer-associated fibroblast subtype and risk signature as predictors of prognosis and treatment effectiveness in gastric cancer","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1340124","article-title":"Cancer-associated fibroblasts: Protagonists of the tumor microenvironment in gastric cancer","volume":"11","author":"Ozmen","year":"2024","journal-title":"Front Mol Biosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-19-0311","article-title":"Tumor immune microenvironment and chemosensitivity signature for predicting response to chemotherapy in gastric cancer","volume":"7","author":"Jiang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1159\/000545429","article-title":"Differential expression of immune checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on circulating natural killer cells - Insights from healthy donors compared to gastric cancer patients","volume":"48","author":"Seiffert","year":"2025","journal-title":"Oncol Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108551","article-title":"The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer","volume":"219","author":"Fan","year":"2020","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1611234","article-title":"Immunopharmacology of gastric cancer-deciphering immune cell subset responses and nanoparticle-mediated targeting","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.01.008","article-title":"Fibroblast-derived LPP as a biomarker for treatment response and therapeutic target in gastric cancer","volume":"24","author":"Wang","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.12659\/msm.916432","article-title":"Association between intra-tumoral immune response and programmed death ligand 1 (PD-L1) in gastric cancer","volume":"25","author":"Yan","year":"2019","journal-title":"Med Sci Monitor: Int Med J Exp Clin Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s13577-025-01316-6","article-title":"The \"dual personality\" of LOXL3: A tumor accomplice and a new hope for immunotherapy","volume":"39","author":"Wu","year":"2025","journal-title":"Hum Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03290-0","article-title":"Immunosuppressive immune microenvironment landscapes in VISTA-high gastric cancer","volume":"134","author":"Luo","year":"2026","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1578","article-title":"Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer","volume":"14","author":"Cao","year":"2024","journal-title":"Clin Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17752","article-title":"Clinical significance of PD-L1, LAG3, and VISTA in patients with poorly cohesive cell gastric cancer","volume":"45","author":"Lee","year":"2025","journal-title":"Anticancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/cancers14071736","article-title":"Interspatial distribution of tumor and immune cells in correlation with PD-L1 in molecular subtypes of gastric cancers","volume":"14","author":"Dislich","year":"2022","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/cancers10040102","article-title":"EBV(+) and MSI gastric cancers harbor high PD-L1\/PD-1 expression and high CD8(+) intratumoral lymphocytes","volume":"10","author":"De Rosa","year":"2018","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2684065","article-title":"Prevalence of Epstein-Barr virus infection and mismatch repair protein deficiency and the correlation of immune markers in Tibetan patients with gastric cancer","volume":"2022","author":"Shi","year":"2022","journal-title":"BioMed Res Int"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41598-021-81667-w","article-title":"PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms","volume":"11","author":"Nakano","year":"2021","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3390\/ijms19072079","article-title":"The transcriptomic landscape of gastric cancer: Insights into Epstein-Barr virus infected and microsatellite unstable tumors","volume":"19","author":"Gullo","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3892\/ol.2026.15472","article-title":"Immune microenvironment and treatment response of dMMR gastric cancer: Heterogeneity and implications for immunotherapy","volume":"31","author":"Wang","year":"2026","journal-title":"Oncol Lett"},{"key":"B38","doi-asserted-by":"publisher","first-page":"30932","DOI":"10.1038\/s41598-024-81764-6","article-title":"Association of PD-L1 positivity with Epstein Barr virus infection and microsatellite instability in gastric carcinomas with lymphoid stroma","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.317","article-title":"Effector function characteristics of exhausted CD8+ T-cell in microsatellite stable and unstable gastric cancer","volume":"56","author":"Han","year":"2024","journal-title":"Cancer Res Treat"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001779","article-title":"Human leukocyte antigen class I deficiency in gastric carcinoma: An adaptive immune evasion strategy most common in microsatellite instable tumors","volume":"45","author":"Iwasaki","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13046-025-03513-5","article-title":"TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity","volume":"44","author":"Niu","year":"2025","journal-title":"J Exp Clin Cancer Research: CR"},{"key":"B42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15384047.2022.2038002","article-title":"Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan","volume":"23","author":"Yoshida","year":"2022","journal-title":"Cancer Biol Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000326","article-title":"Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability","volume":"3","author":"Cho","year":"2018","journal-title":"ESMO Open"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00314","article-title":"Tumor mutational burden determined by panel sequencing predicts survival after immunotherapy in patients with advanced gastric cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1862520","article-title":"M1-like TAMs are required for the efficacy of PD-L1\/PD-1 blockades in gastric cancer","volume":"10","author":"Zhao","year":"2020","journal-title":"Oncoimmunology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/pai.0000000000000761","article-title":"Expression of indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophanyl-tRNA synthetase (WARS) in gastric cancer molecular subtypes","volume":"28","author":"Lu","year":"2020","journal-title":"Appl Immunohistochemistry Mol Morphology: AIMM"},{"key":"B47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21037\/tgh.2020.01.08","article-title":"Gastrointestinal cancers: Current biomarkers in esophageal and gastric adenocarcinoma","volume":"5","author":"Dhakras","year":"2020","journal-title":"Trans Gastroenterol Hepatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155743","article-title":"Immune biomarkers and predictive signatures in gastric cancer: Optimizing immunotherapy responses","volume":"265","author":"Vickram","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/ijms19061602","article-title":"Immunotherapy for gastric cancer: Time for a personalized approach","volume":"19","author":"Dolcetti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1599908","article-title":"Predictive biomarkers in the era of immunotherapy for gastric cancer: Current achievements and future perspectives","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1349459","article-title":"Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients","volume":"15","author":"Sun","year":"2024","journal-title":"Front Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20220418-00261","article-title":"Clinical analysis of immunotherapy rechallenge in advanced gastric cancer","volume":"45","author":"Zhang","year":"2023","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2026.100307","article-title":"Readministration of nivolumab for patients with advanced gastric cancer: a case series","volume":"11","author":"Kodama","year":"2026","journal-title":"ESMO Gastrointest Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-023-01011-5","article-title":"Nivolumab rechallenge after prior nivolumab therapy in advanced gastric cancer: a single-center case series and literature review","volume":"55","author":"Tsuji","year":"2024","journal-title":"J Gastrointestinal Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2275","article-title":"Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors","volume":"28","author":"Palmer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1697712","article-title":"Efficacy and safety of immunotherapy rechallenge in second-line treatment after failure of first-line immune checkpoint inhibitors combined with chemotherapy in advanced gastric cancer: a retrospective study","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70222","article-title":"The effect of common medications on the efficacy of immune checkpoint inhibitors","volume":"131","author":"Brinzevich","year":"2025","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s13046-021-02133-z","article-title":"Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy","volume":"40","author":"Jensen","year":"2021","journal-title":"J Exp Clin Cancer Research: CR"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e011346","DOI":"10.1136\/jitc-2024-011346","article-title":"Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction","volume":"13","author":"Zhang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e006464","DOI":"10.1136\/jitc-2022-006464","article-title":"Predictive biomarkers for PD-1\/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data","volume":"11","author":"So","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.08.008","article-title":"Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy","volume":"86","author":"Im","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2162229","article-title":"Associations of clinical and molecular characteristics with the response to immune checkpoint blockade in advanced gastric cancers","volume":"2022","author":"Xu","year":"2022","journal-title":"J Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102315","article-title":"Addressing clinical needs in NSCLC immunotherapy: mechanisms of resistance and promising combination strategies","volume":"6","author":"Kang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00706-y","article-title":"Challenging dermatologic considerations associated with immune checkpoint inhibitors","volume":"23","author":"Park","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241266156","article-title":"Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer","volume":"16","author":"He","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1926-2","article-title":"Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series","volume":"66","author":"Spain","year":"2017","journal-title":"Cancer Immunology Immunotherapy: CII"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14091","article-title":"Rechallenge with checkpoint inhibitors in metastatic melanoma","volume":"18","author":"Reschke","year":"2020","journal-title":"J der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15209","article-title":"Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"15","author":"Lin","year":"2024","journal-title":"Thorac Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10688-0","article-title":"Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e003795","DOI":"10.1136\/rmdopen-2023-003795","article-title":"Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study","volume":"9","author":"Ladouceur","year":"2023","journal-title":"RMD Open"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70324","article-title":"Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: a systematic review and meta-analysis","volume":"13","author":"Xu","year":"2024","journal-title":"Cancer Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267572","article-title":"Effects of immune checkpoint inhibitor therapy resumption in patients with Malignant tumors after moderate-to-severe immune-related adverse events","volume":"17","author":"Kawahira","year":"2022","journal-title":"PloS One"},{"key":"B76","doi-asserted-by":"publisher","first-page":"688","DOI":"10.5306\/wjco.v12.i8.688","article-title":"Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: analysis in western patients after curative-intent surgery","volume":"12","author":"Ramos","year":"2021","journal-title":"World J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70863","article-title":"Immunohistochemical-based molecular typing of ACRG combined with immune-associated PD-L1 expression can predict the prognosis of gastric cancer","volume":"14","author":"Li","year":"2025","journal-title":"Cancer Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1186\/s12885-024-13236-z","article-title":"Prognostic effect of immunohistochemically determined molecular subtypes in gastric cancer","volume":"24","author":"Brodkin","year":"2024","journal-title":"BMC Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/cancers16010055","article-title":"Implementing an on-slide molecular classification of gastric cancer: a tissue microarray study","volume":"16","author":"Costache","year":"2023","journal-title":"Cancers"},{"key":"B80","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-020-01219-0","article-title":"Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance","volume":"19","author":"Yuan","year":"2020","journal-title":"Mol Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1355269","article-title":"Dissecting gastric cancer heterogeneity and exploring therapeutic strategies using bulk and single-cell transcriptomic analysis and experimental validation of tumor microenvironment and metabolic interplay","volume":"15","author":"Lin","year":"2024","journal-title":"Front Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12891","article-title":"Immune therapeutics in the treatment of advanced gastric and esophageal cancer","volume":"38","author":"Park","year":"2018","journal-title":"Anticancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1574010","article-title":"Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist's perspective","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12523","article-title":"Gastric cancer: basic aspects","volume":"23","author":"Duarte","year":"2018","journal-title":"Helicobacter"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.70072","article-title":"Disease burden of gastrointestinal tumors in China from 1990 to 2021, an analysis for the Global Burden of Disease Study 2021","volume":"18","author":"Guo","year":"2025","journal-title":"J Evidence-Based Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238836","article-title":"Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray","volume":"15","author":"Zhao","year":"2020","journal-title":"PloS One"},{"key":"B87","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13578-020-00454-8","article-title":"Inverse correlation between interleukin-34 and gastric cancer, a potential biomarker for prognosis","volume":"10","author":"Liu","year":"2020","journal-title":"Cell Bioscience"},{"key":"B88","doi-asserted-by":"publisher","first-page":"886\u2013904","DOI":"10.1136\/gutjnl-2025-337247","article-title":"Integrative proteogenomics maps multifactorial aetiology, progression and therapeutic vulnerabilities in gastric cancer","volume":"75","author":"Chang","year":"2026","journal-title":"Gut"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.881015","article-title":"Identification by bioinformatics analysis of potential key genes related to the progression and prognosis of gastric cancer","volume":"12","author":"Gao","year":"2022","journal-title":"Front Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/qub2.45","article-title":"Hierarchical learning of gastric cancer molecular subtypes by integrating multi-modal DNA-level omics data and clinical stratification","volume":"12","author":"Yang","year":"2024","journal-title":"Quantitative Biol (Beijing China)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1690200","article-title":"Deep learning and multi-omics reveal programmed cell death-associated diagnostic signatures and prognostic biomarkers in gastric cancer","volume":"16","author":"Jin","year":"2025","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/cji.0000000000000539","article-title":"Single-cell RNA sequencing analysis reveals cancer-associated fibroblast signature for prediction of clinical outcomes and immunotherapy in gastric cancer","volume":"48","author":"Li","year":"2025","journal-title":"J Immunotherapy (Hagerstown Md: 1997)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70572","article-title":"Multiomics-driven drug-cell interaction network for chemotherapy sensitivity prediction in metabolically defined triple-negative breast cancer subtypes","volume":"29","author":"Zhang","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S581764","article-title":"Artificial intelligence for predicting immunotherapy efficacy in non-small cell lung cancer","volume":"19","author":"Cao","year":"2026","journal-title":"J Inflammation Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-026-00922-2","article-title":"Advancing AI for multi-omics and clinical data integration in basic and translational cancer research","author":"Liu","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.3390\/cancers16132448","article-title":"Integrating omics data and AI for cancer diagnosis and prognosis","volume":"16","author":"Ozaki","year":"2024","journal-title":"Cancers"},{"key":"B97","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-023-01514-5","article-title":"Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2021.06.007","article-title":"Hedgehog transcriptional effector GLI mediates mTOR-induced PD-L1 expression in gastric cancer organoids","volume":"518","author":"Koh","year":"2021","journal-title":"Cancer Lett"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.762184","article-title":"Patient-derived organoids in precision medicine: drug screening, organoid-on-a-chip and living organoid biobank","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41698-025-01082-6","article-title":"PharmaFormer predicts clinical drug responses through transfer learning guided by patient derived organoid","volume":"9","author":"Zhou","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000698","article-title":"Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability","volume":"40","author":"Ma","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.1401","article-title":"Unsuccessful rechallenge with nivolumab in a patient with advanced non-small cell lung cancer who had a 6-year complete response and treatment-free period: Case report","volume":"12","author":"Takakura","year":"2024","journal-title":"Respirology Case Rep"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102124","article-title":"Checkpoint inhibitor rechallenge in advanced endometrial cancer: Revisiting the immune landscape beyond first-line therapy","volume":"35","author":"Podder","year":"2025","journal-title":"Int J Gynecological Cancer: Off J Int Gynecological Cancer Soc"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1778","article-title":"Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint-inhibitor pneumonitis: A case report and literature review","volume":"6","author":"Nair","year":"2023","journal-title":"Cancer Rep (Hoboken NJ)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301931","article-title":"The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small-cell lung cancer: Meta-analyses of controlled clinical trials","volume":"19","author":"Kong","year":"2024","journal-title":"PloS One"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100309","article-title":"Heterogeneous outcomes of immune checkpoint inhibitor rechallenge in patients with NSCLC: A systematic review and meta-analysis","volume":"3","author":"Xu","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14309","article-title":"Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer","volume":"13","author":"Takahara","year":"2022","journal-title":"Thorac Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01241-z","article-title":"Immune checkpoint inhibitor rechallenge and resumption: A systematic review","volume":"24","author":"Plazy","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1766921","article-title":"Advancing immune checkpoint inhibitor rechallenge: Key insights into efficacy, safety, and personalized strategies in advanced solid tumors","volume":"16","author":"Lu","year":"2026","journal-title":"Front Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1675745","article-title":"Integrated molecular and microenvironmental drivers of drug resistance in gastrointestinal cancers: Mechanisms, immunotherapy challenges, and precision strategies","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01483-7","article-title":"Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study","volume":"42","author":"Xu","year":"2024","journal-title":"Invest New Drugs"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.002","article-title":"Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation","volume":"35","author":"Peters","year":"2024","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1200466","article-title":"The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer","volume":"11","author":"Xie","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.S568816","article-title":"Comparative retrospective analysis of immunotherapy combined with anti-angiogenic agents and nab-paclitaxel in metastatic gastroesophageal junction adenocarcinoma","volume":"19","author":"Hong","year":"2026","journal-title":"Int J Gen Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v18.i1.112944","article-title":"Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites","volume":"18","author":"Matsumoto","year":"2026","journal-title":"World J Gastrointestinal Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2017.12.005","article-title":"Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine","volume":"1869","author":"Praharaj","year":"2018","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"32","DOI":"10.20517\/cdr.2025.34","article-title":"Modeling methods of different tumor organoids and their application in tumor drug resistance research","volume":"8","author":"Yang","year":"2025","journal-title":"Cancer Drug Resistance (Alhambra Calif)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114098","article-title":"Targeting cancer drug resistance utilizing organoid technology","volume":"158","author":"Chai","year":"2023","journal-title":"Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B119","doi-asserted-by":"publisher","first-page":"46","DOI":"10.20517\/cdr.2024.103","article-title":"HDAC-driven mechanisms in anticancer resistance: Epigenetics and beyond","volume":"7","author":"Minisini","year":"2024","journal-title":"Cancer Drug Resistance (Alhambra Calif)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.25881","article-title":"KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance","volume":"14","author":"Xu","year":"2018","journal-title":"Int J Biol Sci"},{"key":"B121","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B122","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41416-021-01364-3","article-title":"Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers","volume":"125","author":"Takashima","year":"2021","journal-title":"Br J Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v11.i11.957","article-title":"Non-coding RNA in drug resistance of gastric cancer","volume":"11","author":"Luo","year":"2019","journal-title":"World J Gastrointestinal Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2021-0020","article-title":"Resistance to platinum-based cancer drugs: A special focus on epigenetic mechanisms","volume":"22","author":"Mora","year":"2021","journal-title":"Pharmacogenomics"},{"key":"B125","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41419-025-07900-w","article-title":"Epidrug screening identifies type I PRMT inhibitors as modulators of lysosomal exocytosis and drug sensitivity in cancers","volume":"16","author":"Sergi","year":"2025","journal-title":"Cell Death Dis"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1753749","article-title":"Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13503","article-title":"Nivolumab rechallenge after immune-related adverse events in patients with unresectable advanced or recurrent esophageal cancer","volume":"38","author":"Ueno","year":"2024","journal-title":"In Vivo (Athens Greece)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1820652\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:46:27Z","timestamp":1779255987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1820652\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":127,"alternative-id":["10.3389\/fimmu.2026.1820652"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1820652","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1820652"}}